Phase 4Active, not recruiting
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
- Sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 200 planned
- Conditions
- Psoriatic Arthritis; Overweight or Obesity
- Interventions
- Tirzepatide
- Ages
- adults, older adults
- Registry
- NCT06864026
Full record on ClinicalTrials.gov
From the registry
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Primary outcomes
- Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy
- Percentage of Participants Achieving at Least a 10% Weight Loss at 12 Months of Therapy
History
Primary completion expected
Last registry update
Registered
Started